All Stories

  1. Stable isotope labeling and ultra-high-resolution NanoSIMS imaging reveal alpha-synuclein-induced changes in neuronal metabolism in vivo
  2. Recovery of walking after paralysis by regenerating characterized neurons to their natural target region
  3. Mitofusin-2 in nucleus accumbens D2-MSNs regulates social dominance and neuronal function
  4. Rapid ex vivo reverse genetics identifies the essential determinants of prion protein toxicity
  5. Rapid ex vivo reverse genetics identifies the essential determinants of prion protein toxicity
  6. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy
  7. Astrocyte‐targeting RNA interference against mutated superoxide dismutase 1 induces motoneuron plasticity and protects fast‐fatigable motor units in a mouse model of amyotrophic lateral sclerosis
  8. Dopamine and Methamphetamine Differentially Affect Electron Transport Chain Complexes and Parkin in Rat Striatum: New Insight into Methamphetamine Neurotoxicity
  9. The exercise-induced long noncoding RNA CYTOR promotes fast-twitch myogenesis in aging
  10. Mitofusin-2 in the Nucleus Accumbens Regulates Anxiety and Depression-like Behaviors Through Mitochondrial and Neuronal Actions
  11. The Links between ALS and NF-κB
  12. Anti-Aβ antibodies bound to neuritic plaques enhance microglia activity and mitigate tau pathology
  13. Nano-imaging trace elements at organelle levels in substantia nigra overexpressing α-synuclein to model Parkinson’s disease
  14. Glutaredoxin1 Diminishes Amyloid Beta-Mediated Oxidation of F-Actin and Reverses Cognitive Deficits in an Alzheimer's Disease Mouse Model
  15. Allele-specific gene editing prevents deafness in a model of dominant progressive hearing loss
  16. Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells
  17. The RNA-Binding Protein PUM2 Impairs Mitochondrial Dynamics and Mitophagy During Aging
  18. Altered interplay between endoplasmic reticulum and mitochondria in Charcot–Marie–Tooth type 2A neuropathy
  19. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: Converging roads to therapeutic development
  20. Exogenous LRRK2G2019S induces parkinsonian-like pathology in a nonhuman primate
  21. PM20D1 is a quantitative trait locus associated with Alzheimer’s disease
  22. Cortico–reticulo–spinal circuit reorganization enables functional recovery after severe spinal cord contusion
  23. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship?
  24. PFN2 and GAMT as common molecular determinants of axonal Charcot-Marie-Tooth disease
  25. Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis
  26. Scalable Production and Purification of Adeno-Associated Viral Vectors (AAV)
  27. Alpha-synuclein ferrireductase activity is detectible in vivo, is altered in Parkinson's disease and increases the neurotoxicity of DOPAL
  28. Modulating the catalytic activity of AMPK has neuroprotective effects against α-synuclein toxicity
  29. In vivo neurochemical measurements in cerebral tissues using a droplet-based monitoring system
  30. G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain
  31. Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects
  32. An R-CaMP1.07 reporter mouse for cell-type-specific expression of a sensitive red fluorescent calcium indicator
  33. α-Synuclein increases β-amyloid secretion by promoting β-/γ-secretase processing of APP
  34. Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neurons
  35. Un implant bioactif pour prévenir la maladie d’Alzheimer
  36. Gene Therapy: A Promising Approach for Neuroprotection in Parkinson’s Disease?
  37. Axonal Localization of Integrins in the CNS Is Neuronal Type and Age Dependent
  38. Amyloid-β plaque deposition measured using propagation-based X-ray phase contrast CT imaging
  39. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies
  40. Spinal cord stimulation improves forelimb use in an alpha-synuclein animal model of Parkinson's disease
  41. Regulation of Memory Formation by the Transcription Factor XBP1
  42. In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons
  43. Lentiviral Vectors for the Engineering of Implantable Cells Secreting Recombinant Antibodies
  44. Αlpha-Synuclein as a Mediator in the Interplay between Aging and Parkinson’s Disease
  45. Chondroitinase gene therapy improves upper limb function following cervical contusion injury
  46. Tmc gene therapy restores auditory function in deaf mice
  47. Pathway-specific reorganization of projection neurons in somatosensory cortex during learning
  48. Encapsulated Cellular Implants for Recombinant Protein Delivery and Therapeutic Modulation of the Immune System
  49. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease
  50. PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein
  51. Channel-Mediated Lactate Release by K+-Stimulated Astrocytes
  52. Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology
  53. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice
  54. Marinesco-Sjögren syndrome protein SIL1 regulates motor neuron subtype-selective ER stress in ALS
  55. α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)
  56. The adipocyte differentiation protein APMAP is an endogenous suppressor of A  production in the brain
  57. Overview of Mouse Models of Parkinson's Disease
  58. Loss of MITF expression during human embryonic stem cell differentiation disrupts retinal pigment epithelium development and optic vesicle cell proliferation
  59. A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity
  60. Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1
  61. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration
  62. Large-Scale Chondroitin Sulfate Proteoglycan Digestion with Chondroitinase Gene Therapy Leads to Reduced Pathology and Modulates Macrophage Phenotype following Spinal Cord Contusion Injury
  63. Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type–Specific Transgene Expression in the Spinal Cord
  64. A high-capacity cell macroencapsulation system supporting the long-term survival of genetically engineered allogeneic cells
  65. Genetic engineering of cell lines using lentiviral vectors to achieve antibody secretion following encapsulated implantation
  66. Measurement of autophagy flux in the nervous system in vivo
  67. FOXO3 determines the accumulation of  -synuclein and controls the fate of dopaminergic neurons in the substantia nigra
  68. Application of Viral Vectors to Motor Neuron Disorders
  69. Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity
  70. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo
  71. Behaviour-dependent recruitment of long-range projection neurons in somatosensory cortex
  72. Dysregulation of voltage-gated sodium channels by ubiquitin ligase NEDD4-2 in neuropathic pain
  73. Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles
  74. Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model
  75. Proton and Phosphorus Magnetic Resonance Spectroscopy of a Mouse Model of Alzheimer's Disease
  76. Overexpression of tau in the mouse forebrain using adeno-associated virus (AAV) leads to tau hyperphosphorylation, formation of neurofibrillary tangles and neurodegeneration
  77. Anin vivoultrahigh field 14.1 T1H-MRS study on 6-OHDA and α-synuclein-based rat models of Parkinson's disease: GABA as an early disease marker
  78. Endoplasmic Reticulum Stress Is Important for the Manifestations of  -Synucleinopathy In Vivo
  79. Nigrostriatal overabundance of α-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity
  80.  -Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer
  81. Mimicking Phosphorylation at Serine 87 Inhibits the Aggregation of Human  -Synuclein and Protects against Its Toxicity in a Rat Model of Parkinson's Disease
  82. Parkinson's Disease: Gene Therapies
  83. Sustained expression of PGC-1  in the rat nigrostriatal system selectively impairs dopaminergic function
  84. Lentiviral vectors express chondroitinase ABC in cortical projections and promote sprouting of injured corticospinal axons
  85. Behavioral and neuropathological characterization of a viral-based model of amyloid pathology
  86. Modelling Alzheimer's disease through Adeno-Associated Virus (AAV) vector gene delivery in the mouse brain
  87. Neuroprotection by Gene Therapy Targeting Mutant SOD1 in Individual Pools of Motor Neurons Does not Translate Into Therapeutic Benefit in fALS Mice
  88. A Rat Model of Progressive Nigral Neurodegeneration Induced by the Parkinson's Disease-Associated G2019S Mutation in LRRK2
  89. Rab1A Over-Expression Prevents Golgi Apparatus Fragmentation and Partially Corrects Motor Deficits in an Alpha-Synuclein Based Rat Model of Parkinson's Disease
  90. Long-range connectivity of mouse primary somatosensory barrel cortex
  91. Phosphorylation at S87 Is Enhanced in Synucleinopathies, Inhibits  -Synuclein Oligomerization, and Influences Synuclein-Membrane Interactions
  92. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6
  93. Targeted overexpression of the parkin substrate Pael-R in the nigrostriatal system of adult rats to model Parkinson's disease
  94. Phosphorylation Does Not Prompt, Nor Prevent, the Formation of  -synuclein Toxic Species in a Rat Model of Parkinson's Disease
  95. Regulation of Prenatal Human Retinal Neurosphere Growth and Cell Fate Potential by Retinal Pigment Epithelium and Mash1
  96. Viral vectors, animal models and new therapies for Parkinson's disease
  97. Systemic AAV6 Delivery Mediating RNA Interference Against SOD1: Neuromuscular Transduction Does Not Alter Disease Progression in fALS Mice
  98. Viral Vectors
  99. Lentiviral vector-mediated genetic modification of human neural progenitor cells for ex vivo gene therapy
  100. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation
  101. Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease
  102. Inducing Tolerance to a Soluble Foreign Antigen by Encapsulated Cell Transplants
  103. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates
  104. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-synuclein rat model of Parkinson's disease
  105. Survival of Encapsulated Human Primary Fibroblasts and Erythropoietin Expression Under Xenogeneic Conditions
  106. Wlds-Mediated Protection of Dopaminergic Fibers in an Animal Model of Parkinson Disease
  107. Wlds-Mediated Protection of Dopaminergic Fibers in an Animal Model of Parkinson Disease
  108. Using human neural stem cells to model neurological disease
  109. Prevention of the initial host immuno-inflammatory response determines the long-term survival of encapsulated myoblasts genetically engineered for erythropoietin delivery
  110. Cellular implants: pioneers in xenotransplantation?
  111. Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia
  112. Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia
  113. Long-Term Doxycycline-Regulated Secretion of Erythropoietin by Encapsulated Myoblasts
  114. α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease
  115. Encapsulation as a Strategy for Cell Xenotransplantation
  116. INDUCING HOST ACCEPTANCE TO ENCAPSULATED XENOGENEIC MYOBLASTS
  117. A self-immunomodulating myoblast cell line for erythropoietin delivery
  118. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts